We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Maria
Zamora Morales
luigi.aloj@nhs.net
Luigi
Aloj
luigi.aloj@nhs.net
Johanna
Field-Rayner
luigi.aloj@nhs.net
Marta
Wylot
luigi.aloj@nhs.net
Elisabeth
Crowe
luigi.aloj@nhs.net
Malignant neoplasms of female genital organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Ovarian cancer cells typically carry protein on their cell surface, namely CA125 (cancer-antigen 125). CA125 can be measured in the blood, and a CA125 blood test can therefore be used to help diagnose ovarian cancer, monitor treatment response and disease recurrence. However, CA125 concentrations in the blood do not reflect the extent of cancer within the body nor can they be used to identify the anatomical location of tumour cells. Knowledge of the exact tumour amount and location could improve treatment planning and surgery.
Positron emission tomography (PET) and magnetic resonance imaging (MRI) are medical imaging methods that can be used to picture cancers and provide information about how tumours function. PET and MRI scans are routinely used in hospitals to detect various cancers, and a PET/MR scan combines these two types of scans into a single examination. To show the activity of the cancer, a mildly radioactive drug (a radiotracer) is used for PET/MRI scanning. The radiotracer used in this study, 89Zr-DFO-B43.13, binds more to cancer cells than normal cells, because cancers display its target protein CA125 on their cell surface while normal cells do not.
This study aims to use a type of scan called an 89Zr-DFO-B43.13 PET/MRI scan in ovarian cancer. We wish to test the ability of this type of scan in identifying the anatomical locations of tumour cells and the extent of ovarian cancer, as this can enable doctors to decide the best course for treatment for each patient. We also wish to compare the results we will be getting from the PET/MRI images, with the results from blood tests and the examination of the tumour tissue following your surgery.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Validation of investigation /therapeutic procedures;
You can take part if:
You may not be able to take part if:
• Previous treatment with B43.13 • Active central nervous system involvement • Life expectancy < 3 months • Patients who cannot undergo surgery • Pregnant or breastfeeding • Not suitable for MR scanning e.g. severe obesity, inability to lie still or contraindicated metal implants such as the intrauterine contraceptive device. • Lack of availability for follow-up assessments • Vulnerable patient groups; • Unable to provide informed consent. • Presence of human anti mouse anti-body (HAMA) in serum
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Elisabeth
Crowe
luigi.aloj@nhs.net
Luigi
Aloj
luigi.aloj@nhs.net
Marta
Wylot
luigi.aloj@nhs.net
Johanna
Field-Rayner
luigi.aloj@nhs.net
Maria
Zamora Morales
luigi.aloj@nhs.net
The study is sponsored by CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST and funded by CANCER RESEARCH UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 41270
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
